We're buying this stock for the second time this week, taking advantage post-earnings selling

  • 📰 CNBC
  • ⏱ Reading Time:
  • 22 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 29%
  • Publisher: 72%

Breaking News: Markets News

Markets,Investment Strategy,Jim Cramer

The roughly 10% decline in shares since earnings is too excessive.

We're buying 25 shares of Danaher at roughly $243 each. Following Thursday's trade, Jim Cramer's Charitable Trust will own 525 shares of DHR, increasing its weighting to 3.67% from 3.5%. We're picking up more shares of Danaher as we continue to view the roughly 10% decline in shares of the life sciences company since earnings as too excessive and a chance to add to our position for the second time this week at a cheaper price.

On Thursday morning, Wolfe Research upgraded its rating on Danaher to an outperform buy and set a $285 per share price target. Even though Wolfe said it has always believed Danaher was one of the top assets in the tools industry, it held a peer perform hold rating on the stock because the analysts thought consensus expectations and the stock's valuation were too high. That has all changed in the past week.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines